The DHEA Sulphate (DHEAS) Blood Test segmentation by application delineates four primary clinical uses that together drive market volume. Hormonal disorder diagnosis accounts for the largest share, as endocrinologists rely on DHEAS levels to differentiate primary adrenal insufficiency, polycystic ovary syndrome, and hyperandrogenic states; this application generates roughly 40 % of test orders. Anti‑aging assessment leverages the age‑related decline of DHEAS as a biomarker for physiological senescence, supporting wellness clinics and geriatric practices, contributing about 25 % of the market. Fertility evaluation uses DHEAS to predict ovarian reserve and assisted‑reproduction outcomes, representing an estimated 20 % share. Finally, Adrenal function monitoring in intensive‑care and surgical settings tracks acute stress responses, comprising the remaining 15 %. Each segment influences total market size through distinct payer mixes, reimbursement rates, and testing frequencies, underscoring the importance of application‑driven demand in the overall market landscape.